TG Therapeutics Inc
NASDAQ:TGTX
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
12.49
35.07
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
TG Therapeutics Inc
TG Therapeutics Inc
Total Equity
TG Therapeutics Inc
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
TG Therapeutics Inc
NASDAQ:TGTX
|
Total Equity
$177.6m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
10%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Equity
$6B
|
CAGR 3-Years
-24%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
3%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Equity
$18.4B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
3%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Equity
$7.5B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-11%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Equity
$15.6B
|
CAGR 3-Years
18%
|
CAGR 5-Years
24%
|
CAGR 10-Years
30%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Equity
$29.3B
|
CAGR 3-Years
19%
|
CAGR 5-Years
23%
|
CAGR 10-Years
28%
|
|
TG Therapeutics Inc
Glance View
TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in New York City, New York and currently employs 286 full-time employees. Its pipeline candidates include TG-1501 (Cosibelimab), TG-1701 (BTK inhibitor), TG-1801 (anti-CD47/anti-CD19 bispecific monoclonal antibody). Its UKONIQ (umbralisib) is developed for the treatment of adult patients with relapsed or refractory marginal zone lymphoma who have received at least one prior anti-CD20-based regimen and relapsed or refractory follicular lymphoma. The company has three programs in Phase III development for the treatment of patients with relapsing forms of multiple sclerosis and patients with chronic lymphocytic leukemia and several investigational medicines in Phase I clinical development. The company also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.
See Also
What is TG Therapeutics Inc's Total Equity?
Total Equity
177.6m
USD
Based on the financial report for Sep 30, 2024, TG Therapeutics Inc's Total Equity amounts to 177.6m USD.
What is TG Therapeutics Inc's Total Equity growth rate?
Total Equity CAGR 10Y
10%
Over the last year, the Total Equity growth was 8%. The average annual Total Equity growth rates for TG Therapeutics Inc have been -17% over the past three years , and 10% over the past ten years .
You don't have any saved screeners yet
